ClinicalTrials.gg
Active, not recruitingNCT03066050Updated Nov 20, 2026

Long Term Follow Up for CTSN Mitral Valve Repair Studies

An observational study in Mitral Valve Insufficiency and Coronary Artery Disease, sponsored by Icahn School of Medicine at Mount Sinai. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
368
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.

Enrollment
14th of 37
368 · median 200
Started
2017
with 9 others
Observational
37 of 118
12 open now
Primary completion
2027-07
later than 28 of 52 live
Registered
48th of 118
by date
Lead sponsor
3 of 118
Icahn School of Medicine at Mount Sinai

Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 14th largest by enrollment of the 37 observational ones that give a count, is one of 10 that started in 2017, is one of 37 observational ones, reaches primary completion later than 28 of the 52 other live ones, and was the 48th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Mitral Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study is a continuation of two previous studies --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- to learn more about patients' health 5-10 years after their mitral valve surgeries. The investigators will collect long-term health information on SMR and MMR trial participants using electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases.

Read the detailed description

This study is a continuation of two CTSN randomized trials --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- for the purpose of assessing the long-term outcomes of the index surgical therapies. Key clinical outcomes will be collected utilizing electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases. Extended follow-up data will be obtained on up to 199 SMR and 270 MMR trial participants, who were alive at their 2-year follow-up evaluation. Patients will be followed for a minimum of 5 years and up to 10 years after randomization (the time of index surgical procedure). This follow-up data collection will be conducted by the Cardiothoracic Surgical Trials Network (CTSN) primarily utilizing the minimal PHI necessary to link data obtained from the MMR and SMR trials to other healthcare- and/or vital status-related databases.

Because the design of surgical trials for ischemic mitral regurgitation that would use mortality as a primary endpoint requires the enrollment of thousands of patients, the selected primary endpoint for the CTSN SMR and MMR trials was an echocardiographic measure of left ventricular remodeling. Secondary endpoints included, among others, survival, adverse events, readmissions and costs over a 2-year period. The SMR trial showed no difference in left ventricular reverse remodeling, but the rate of moderate or severe mitral regurgitation recurrence was significantly higher with mitral valve repair, resulting in more heart failure-related adverse events and cardiovascular admissions. Longer-term follow-up will be critical to assess whether this observed trend amongst SMR patients will continue and whether a survival difference will manifest over time. In moderate ischemic mitral regurgitation, mitral valve repair provided a more durable correction of mitral regurgitation than coronary artery bypass grafting (CABG) alone, but repair did not improve survival or reduce overall adverse events or readmissions, and was associated with an early hazard of neurological and supraventricular arrhythmic events. Longer-term follow-up of MMR patients will provide insights into whether the higher degree of recurrent mitral regurgitation with CABG alone will be associated with differences in adverse events, readmissions and survival. Additionally, the benefits of alternative surgical treatments for ischemic mitral regurgitation, which have differential upfront risks and costs, will likely extend beyond 2 years. Cost-effectiveness analysis will delineate the long-term cost-benefit trade-offs between mitral valve repair versus replacement for SMR, and of CABG with repair versus CABG alone for MMR, which should inform surgical decision making, and examine how differences in life expectancy and risk profiles of different patient groups affect cost-effectiveness over time. This extended follow-up should provide important clinical and health policy insights.

03

Conditions studied

  • Mitral Valve Insufficiency
  • Coronary Artery Disease

Keywords

  • Ischemic Mitral Regurgitation
  • Mitral Valve Disease
  • Moderate Mitral Regurgitation
  • Severe Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention

Exclusion criteria

Exclusion Criteria:

  • Patients participating in the MMR and SMR trials who withdrew consent prior to the 2-year follow-up evaluation
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
368 participants (actual)
Patient registry
No

Groups and cohorts

  • SMR MV Repair

    This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.

    Other: MV Repair

  • MV Replacement

    This group of patients had been randomized in the SMR study to mitral valve replacement.

    Other: MV Replacement

  • MMR MV Repair

    This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.

    Other: MV Repair

  • CABG

    This group of patients had been randomized in the MMR study to receive CABG

    Other: CABG

Interventions

  • OtherMV Repair

    Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

    Also known as: Mitral Valve Repair

  • OtherMV Replacement

    Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.

    Also known as: Mitral Valve Replacement

  • OtherCABG

    Participants underwent coronary artery bypass grafting

    Also known as: Coronary Artery Bypass Grafting

06

What researchers measure

Primary outcomes

  1. Survival

    All-cause mortality will be assessed.

    Time frame: up to 10 years post-surgery (at the time of registry data transfer)

Secondary outcomes

  1. Repeat Cardiac Interventions for MR

    Repeat cardiac interventions for MR in particular will be determined for the duration of follow-up and will be analyzed using a time-to-event analysis.

    Time frame: up to 10 years post-surgery (at the time of registry data transfer)

  2. Hospital Costs

    Hospital costs will be calculated for the duration of follow-up utilizing the minimum PHI necessary to link the CTSN databases to other databases (e.g., Vizient, CMS Medicare, and Canadian Province databases). Cost data will be extracted from the Vizient operational database system for member sites or national payer or state-wide databases. Dates of charges and revenue codes will be used to match the cost data with data on readmissions. We will estimate costs including center-specific ratios of cost to charges. These ratios will be based on the annual Medicare costs reports submitted annually by participating study sites to Medicare. These data will be used to impute data for patients treated at hospitals, which are non-Vizient members.

    Time frame: up to 10 years post-surgery (at the time of registry data transfer)

  3. Cost Effectiveness

    Cost Effectiveness using Incremental Cost Effectiveness Ratio and Net Health Benefit parameters. The primary objective of the cost-effectiveness analysis (CEA) is to estimate the incremental cost-effectiveness ratio (ICER) of the intervention under investigation as compared to the study-defined alternative. This ratio measures the ratio of the difference in costs and outcomes between the two study arms for each trial, with outcomes measured as life-years. We will also compute net health benefits (NHB) as an alternative way of looking at cost-effectiveness. This parameter compares the incremental effectiveness of an intervention with the minimum health effect that society would demand in return for the investment; i.e., with the health produced by investing at the societal ceiling cost-effectiveness ratio.

    Time frame: up to 10 years post-surgery (at the time of registry data transfer)

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2017 (actual). Primary completion is estimated for Jul 2027, 122 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 122 months is above that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2017
First posted
Feb 28, 2017
StartActual
May 3, 2017
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03066050
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Canadian Institutes of Health Research (CIHR)
Responsible party
Annetine Gelijns (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Feb 28, 2017
Start date
May 3, 2017
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Annetine C Gelijns, PhD
principal investigator · Icahn School of Medicine at Mount Sinai
Richard Weisel, MD
study chair · Toronto General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion